The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells

BACKGROUND AND PURPOSE: Vorinostat and romidepsin are histone deacetylase inhibitors (HDI), approved for the treatment of cutaneous T-cell lymphoma (CTCL). However, the mechanism(s) by which these drugs exert their anti-cancer effects are not fully understood. Since CTCL is associated with immune dy...

Full description

Saved in:
Bibliographic Details
Main Authors: Tiffon, CE, Adams, JE, van der Fits, L, Wen, S, Townsend, PA, Ganesan, A, Hodges, E, Vermeer, MH, Packham, G
Format: Artigo
Language:Inglês
Published: Blackwell Science Inc 2011
Subjects:
Research Papers
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3057296/
https://ncbi.nlm.nih.gov/pubmed/21198545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2010.01188.x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items